## **Murat Tuncel**

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8307210/publications.pdf

Version: 2024-02-01

56	1,064	14	32
papers	citations	h-index	g-index
60	60	60	1380
all docs	docs citations	times ranked	citing authors

#	Article	lF	CITATIONS
1	The detection rate of [11C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 18-23.	6.4	355
2	Scintigraphic Evaluation of Salivary Gland Dysfunction in Patients with Thyroid Cancer After Radioiodine Treatment. Clinical Nuclear Medicine, 2002, 27, 767-771.	1.3	114
3	[11C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer. Nuclear Medicine and Biology, 2008, 35, 689-695.	0.6	70
4	Evaluation of outcome prediction and disease extension by quantitative 2-deoxy-2-[18F] fluoro-d-glucose with positron emission tomography in patients with small cell lung cancer. Annals of Nuclear Medicine, 2011, 25, 406-413.	2.2	51
5	Scintigraphic imaging of radiolabelled drug delivery systems in rabbits with arthritis. International Journal of Pharmaceutics, 2005, 296, 34-43.	5.2	36
6	Diagnostic and therapeutic evaluation of folate-targeted paclitaxel and vinorelbine encapsulating theranostic liposomes for non-small cell lung cancer. European Journal of Pharmaceutical Sciences, 2021, 156, 105576.	4.0	36
7	Nanosized multifunctional liposomes for tumor diagnosis and molecular imaging by SPECT/CT. Journal of Liposome Research, 2013, 23, 20-27.	3.3	31
8	Renal Function Assessment During Peptide Receptor Radionuclide Therapy. Seminars in Nuclear Medicine, 2016, 46, 462-478.	4.6	29
9	Nuclear Medicine in Pediatric and Adolescent Tumors. Seminars in Nuclear Medicine, 2016, 46, 308-323.	4.6	23
10	Thyroid Stimulating Hormone Receptor. Molecular Imaging and Radionuclide Therapy, 2017, 26, 87-91.	0.7	22
11	Role of 68-Ga-PSMA-PET/CT in pelvic radiotherapy field definitions for lymph node coverage in prostate cancer patients. Radiotherapy and Oncology, 2020, 151, 222-227.	0.6	18
12	Increased Uptake on I-131 Whole-Body Scintigraphy in Warthin Tumor Despite False-Negative Tc-99m Pertechnetate Salivary Gland Scintigraphy. Clinical Nuclear Medicine, 2003, 28, 945-946.	1.3	16
13	The Comparative Effects of Gene Modulators on Thyroid-Specific Genes and Radioiodine Uptake. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 443-449.	1.0	16
14	Clinical impact of 68Ga-DOTATATE PET-CT imaging in patients with medullary thyroid cancer. Annals of Nuclear Medicine, 2020, 34, 663-674.	2.2	16
15	68Ga-labelled PSMA ligand HBED-CC PET/CT imaging in patients with recurrent prostate cancer. World Journal of Urology, 2019, 37, 813-821.	2.2	15
16	Gamut. Seminars in Nuclear Medicine, 2003, 33, 334-337.	4.6	14
17	The Comparative Effects of Gene Modulators on Thyroid-Specific Genes and Radioiodine Uptake. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 281-288.	1.0	14
18	Osteopoikilosis: a major diagnostic problem solved by bone scintigraphy. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2012, 31, 93-96.	0.0	14

#	Article	IF	CITATIONS
19	Gastroesophageal reflux scintigraphy: interpretation methods and inter-reader agreement. World Journal of Pediatrics, 2011, 7, 245-249.	1.8	13
20	Radiolabeled, folate-conjugated liposomes as tumor imaging agents: Formulation and in vitro evaluation. Journal of Drug Delivery Science and Technology, 2019, 50, 321-328.	3.0	13
21	The role of Tc-99m MIBI scintigraphy in clinical T1 renal mass assessment: Does it have a real benefit?. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 937.e11-937.e17.	1.6	12
22	Gated myocardial perfusion scintigraphy in children with myocarditis: can it be considered as an indicator of clinical outcome?. Nuclear Medicine Communications, 2008, 29, 907-914.	1.1	11
23	Prognosis estimation under the light of metabolic tumor parameters on initial FDG-PET/CT in patients with primary extranodal lymphoma. Radiology and Oncology, 2016, 50, 360-369.	1.7	10
24	Radioguided occult lesion localization in patients with recurrent thyroid cancer. European Archives of Oto-Rhino-Laryngology, 2019, 276, 1757-1766.	1.6	9
25	Bone scintigraphy as a gatekeeper for the detection of bone metastases in patients with prostate cancer: comparison with Ga-68 PSMA PET/CT. Annals of Nuclear Medicine, 2020, 34, 932-941.	2.2	8
26	Predictive factors of tumor sink effect: Insights from 177Lu-Prostate-specific membrane antigen therapy. Annals of Nuclear Medicine, 2021, 35, 529-539.	2.2	8
27	Diagnostic Performance of 99mTc-Methoxy-Isobuty-Isonitrile (MIBI) for Risk Stratification of Hypofunctioning Thyroid Nodules: A European Multicenter Study. Diagnostics, 2022, 12, 1358.	2.6	8
28	Comparison of wire-guided localization and radio-guided occult lesionlocalization in preoperative localization of nonpalpable breast lesions. Turkish Journal of Medical Sciences, 2016, 46, 1829-1837.	0.9	7
29	Role of indocyanine green combined with radiotracer-Technetium 99Âm in neck surgery for primary and recurrent head and neck cancer: preliminary results of a tertiary cancer center. European Archives of Oto-Rhino-Laryngology, 2022, 279, 1549-1560.	1.6	7
30	To give or not to give? A critical appraisal of a clinical trial on radioiodine treatment. European Journal of Nuclear Medicine and Molecular Imaging, 2022, , .	6.4	7
31	Thyroid volumes and serum VEGF levels in dyslipidemic patients: effects of statin treatment. Turkish Journal of Medical Sciences, 2019, 49, 738-745.	0.9	6
32	Clinical parameters and nomograms for predicting lymph node metastasis detected with <sup>68</sup> Gaâ€PSMAâ€PET/CT in prostate cancer patients candidate to definitive radiotherapy. Prostate, 2021, 81, 648-656.	2.3	6
33	Value of Hepatobiliary Scintigraphy After Type 1 Choledochal Cyst Excision and Roux-en-Y Hepatojejunostomy. Clinical Nuclear Medicine, 2006, 31, 93-95.	1.3	5
34	Comparison of clinical and PET-derived prognostic factors in patients with non-Hodgkin lymphoma. Nuclear Medicine Communications, 2020, 41, 540-549.	1.1	4
35	Osteoid Osteoma of the Rib Detected on Bone Scintigraphy. Clinical Nuclear Medicine, 2002, 27, 216-217.	1.3	4
36	Quality Goal for Salvage Treatment for Patients with Prostate Cancer at Prostate-specific Antigen Relapse. European Urology Oncology, 2022, 5, 732-733.	5.4	4

#	Article	IF	Citations
37	Behcet Disease With an Intrapulmonary Shunt. Clinical Nuclear Medicine, 2006, 31, 181-182.	1.3	3
38	SPECT-CT imaging of poliostotic fibrous dysplasia. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2012, 31, 47-48.	0.0	3
39	Stereotactic ablative radiotherapy for bone metastasis of gastrointestinal stromal tumor: Case report and review of the literature. Reports of Practical Oncology and Radiotherapy, 2020, 25, 331-335.	0.6	3
40	A multicenter survey of current practices of 99mTc-methoxy-isobutyl-isonitrile (MIBI) imaging for the diagnosis of thyroid nodules: more standardization is essential. Clinical and Translational Imaging, 2021, 9, 413-422.	2.1	3
41	Selected intra-arterial injection of Tc-99m MDP. Revista Española De Medicina Nuclear, 2004, 23, 284-285.	0.3	3
42	Clinical impact of SPECT-CT on bone scintigraphy in oncology: Pattern approach. Journal of B U on, 2016, 21, 1296-1306.	0.4	3
43	Value of technetium scintigraphy and iodine uptake measurement during follow-up of differentiated thyroid cancer. Annals of Nuclear Medicine, 2004, 18, 479-482.	2.2	2
44	Results of intraoperative gamma probe survey and frozen section in surgical treatment of parathyroid adenoma in children. Journal of Pediatric Surgery, 2016, 51, 1492-1495.	1.6	2
45	Clinical Impact of PET Imaging in Patients With Metastatic Prostate Cancer. Clinical Nuclear Medicine, 2020, 45, 757-764.	1.3	2
46	Using a pessary during radiotherapy in reducible pelvic organ prolapse and vaginal cancer: a case report and review of the literature. Journal of Contemporary Brachytherapy, 2020, 12, 175-180.	0.9	2
47	Preserved Value of Bone Scintigraphy for the Detection of Skeletal Metastases in Prostate Cancer Patients with Low Prostate-Specific Antigen Levels. Clinical Nuclear Medicine, 2002, 27, 532-533.	1.3	2
48	Vascular retention of Tc-99m pertechnetate and Tc-99m sestamibi, mimicking thyroid carcinoma metastases. Revista Española De Medicina Nuclear, 2007, 26, 226-229.	0.3	1
49	Butterfly Vertebra. Clinical Nuclear Medicine, 2010, 35, 293-294.	1.3	1
50	99mTc-MDP uptake in thyroid nodule: Contribution of SPECT-CT and ultrasonography. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2012, 31, 49-50.	0.0	1
51	Nuclear Medicine Techniques in the Diagnosis and Treatment of Diseases of the Musculoskeletal System., 2016,, 213-255.		1
52	Correspondence: Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions. Nuclear Medicine Communications, 2007, 28, 879-880.	1.1	0
53	Valor de las imágenes de 177 Lu-PSMA post-terapia para una interpretación precisa de la respuesta a la terapia con PET/TC con 68 Ga-PSMA. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2018, 37, 114-117.	0.0	O
54	Non-ultrasonographic and Non-radioiodine Imaging Techniques in Thyroid Cancer., 2021, 7, 80-92.		0

#	Article	IF	CITATIONS
55	Can surgical adhesives may cause false positivity in follow-up positron emission tomography after lung cancer resection?. Tuberkuloz Ve Toraks, 2021, 69, 59-64.	0.4	O
56	Prostate Specific Membrane Antigen Based Imaging. , 2021, , 109-129.		0